The MAGNIFY-MS study: MAVENCLAD® tablets in active RMS

N. de Stefano[1], A. Achiron[2], F. Barkhof[3,4], A. Chan[5], T. Derfuss[6], S. Hodgkinson[7], L. Leocani[8], X. Montalban[9,10], A. Prat[11], K. Schmierer[12,13], F. Sellebjerg[14], P. Vermersch[15], H. Wiendl[16], B. Keller[17], S. Roy[18], on behalf of the MAGNIFY-MS study group

[1]Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy; [2]Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel; [3]Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands; [4]UCL Institute of Neurology, London, UK; [5]Bern University Hospital, University of Bern, Bern, Switzerland; [6]Department of Neurology, University Hospital Basel, Basel, Switzerland; [7]Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia; [8]Experimental Neurophysiological Unit, Vita-Salute San Raffaele University, Milan, Italy; [9]Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada; [10]Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain; [11]Department of Neurosciences, Université de Montréal, Montréal, Canada; [12]The Blizard Institute (Neuroscience), Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK; [13]The Royal London Hospital, Barts Health NHS Trust, London, UK; [14]Danish MS Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark; [15]University de Lille, CHU Lille, LIRIC-INSERM U995, FHU Imminent, Lille, France; [16]Department of Neurology, University of Münster, Münster, Germany; [17]Merck KGaA, Darmstadt, Germany; [18]Merck, Aubonne, Switzerland

Disclosure Statement

This study was sponsored by EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany (in the USA), and Merck Serono SA – Geneva, an affiliate of Merck KGaA Darmstadt, Germany (ROW).

Author Disclosure Statement

NdS has received honoraria and consultation fees from Merck Serono S.A., Teva Pharmaceutical Industries, Novartis Pharma AG, BayerSchering AG, Sanofi-Aventis and Serono Symposia International Foundation. **AA** has received honoraria or consulting fees from Biogen, Sanofi-Genzyme, Bayer, Merck, and Roche; and research support from Biogen, Sanofi-Genzyme, Roche, Bayer, and Merck. **FB** is Director of the IAC, contracted to perform blinded MRI analysis and received consultancy fees from Merck, Novartis, Biogen, Roche, TEVA, Synthon, and Genzyme. **AC** has received speaker's honoraria and consultation fees from Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche and Teva. He has received research support from Genzyme and UCB. **TD** serves on scientific advisory boards for Novartis Pharmaceuticals, Merck Serono, Biogen, Sanofi Genzyme, GeNeuro, MedDay, Mitsubishi Pharma, Roche and Bayer Schering Pharma; has received funding for travel and/or speaker honoraria from Biogen, Sanofi Genzyme, Novartis Pharmaceuticals, Merck Serono, Roche and Bayer Schering Pharma; and receives research support from Biogen, Novartis Pharma, the European Union, the Swiss National Foundation, and the Swiss MS Society. **SH** serves on advisory boards for Merck Serono, Biogen, Novartis, Sanofi Genzyme, Roche and Bayer Schering. She has received money for travel and speaker honorarium from Biogen, Sanofi Genzyme, Novartis, Merck Serono, Roche and Bayer Schering Pharma. **LL** has received honoraria for consulting services or speaking activities from Roche, Novartis, Merck KGaA, Biogen, and Almirall. **XM** has been

a steering committee member of clinical trials or participated in advisory boards of clinical trials with Actelion, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon, Roche, Sanofi-Genzyme and Teva Pharmaceutical. **AP** has received honoraria and operating grants from pharmaceutical companies. KS has been PI of trials sponsored by Novartis, Roche, Teva, Medday. Involved in trials sponsored by Biogen, Genzyme, BIAL, Cytokinetics, Canbex. Speaking honoraria from, and/or served in an advisory role for, Biogen, Cinnagen, Merck, Merck Inc., Novartis, Roche, Teva. Supported for attendance of meetings by Genzyme, Merck and Novartis. Research grant support from Biogen and Novartis. **FS** has served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, EMD Serono, Merck, Novartis, Roche, Sanofi Genzyme and Teva. **PV** has received honoraria or consulting fees from Biogen, Sanofi-Genzyme, Bayer, Novartis, Merck, Celgene, Roche and Almirall; and research support from Biogen, Sanofi-Genzyme, Bayer, and Merck. **HW** is a member of Scientific Advisory Boards/Steering Committees for Bayer Healthcare, Biogen Idec, Sanofi Genzyme, Merck Serono, Novartis, Roche, and Teva. He received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Genzyme, Merck Serono, Omniamed, Novartis, and Sanofi Aventis and Teva. He received compensation as a consultant from Biogen Idec, Merck Serono, Novartis, Omniamed, Roche, and Sanofi Genzyme. He has got research supports from Bayer Healthcare, Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi Genzyme, Sanofi US, and Teva Pharma as well as German Ministry for Education and Research (BMBF), German Research Foundation (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, Merck Serono, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (ISKF) Muenster, RE Children's Foundation. **BK** is an employee of Merck KGaA, Darmstadt, Germany. **SR** is an employee of Merck, Aubonne, Switzerland.